Azelastine

Drug Profile

Azelastine

Alternative Names: Afluon; Allergodil; Astelin; Astepro; Astepro Extra Strength; Astepro Once-Daily; Azelastine extra strength; Azelastine HCl; Azelastine hydrochloride; Azelastine nasal spray; MP03-33; MP03-36; Optilast; Optivar; Rhinolast

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Muro Pharmaceutical
  • Developer Meda
  • Class Antiallergics; Phthalazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 12 May 2014 Generic equivalent of Astepro® (intranasal) approved in USA for Allergic rhinitis
  • 20 Mar 2012 The EMA approves azelastine (improved formulation; Astepro®) for Allergic rhinitis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top